Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colorectal Neoplasms | 18 | 2022 | 6971 | 1.010 |
Why?
|
Colostrum | 2 | 2020 | 28 | 0.840 |
Why?
|
Toll-Like Receptor 8 | 2 | 2015 | 98 | 0.810 |
Why?
|
Toll-Like Receptor 7 | 2 | 2015 | 169 | 0.770 |
Why?
|
Immunoglobulins | 3 | 2024 | 855 | 0.770 |
Why?
|
Platelet-Derived Growth Factor | 3 | 2022 | 617 | 0.740 |
Why?
|
Monocytes | 2 | 2020 | 2595 | 0.660 |
Why?
|
Colonic Neoplasms | 6 | 2021 | 2544 | 0.460 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 1 | 2013 | 94 | 0.410 |
Why?
|
Glycolysis | 1 | 2016 | 838 | 0.400 |
Why?
|
TOR Serine-Threonine Kinases | 4 | 2022 | 2066 | 0.380 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 1813 | 0.350 |
Why?
|
Heme Oxygenase-1 | 4 | 2015 | 365 | 0.340 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2022 | 2460 | 0.340 |
Why?
|
Cell Proliferation | 9 | 2018 | 10478 | 0.340 |
Why?
|
Phosphatidylinositol 3-Kinases | 4 | 2022 | 2884 | 0.340 |
Why?
|
Antigens, Neoplasm | 2 | 2016 | 1999 | 0.330 |
Why?
|
Imidazoles | 1 | 2015 | 1168 | 0.320 |
Why?
|
Hyperthermia, Induced | 1 | 2013 | 417 | 0.320 |
Why?
|
Kidney Transplantation | 8 | 2012 | 4300 | 0.320 |
Why?
|
Heat-Shock Proteins | 1 | 2013 | 797 | 0.320 |
Why?
|
Cytokines | 4 | 2020 | 7445 | 0.290 |
Why?
|
Forkhead Transcription Factors | 3 | 2013 | 1623 | 0.280 |
Why?
|
CA-19-9 Antigen | 1 | 2007 | 107 | 0.270 |
Why?
|
Peritoneal Neoplasms | 1 | 2013 | 715 | 0.270 |
Why?
|
Cyclosporine | 3 | 2011 | 779 | 0.260 |
Why?
|
Carcinoembryonic Antigen | 1 | 2007 | 338 | 0.250 |
Why?
|
Apoptosis | 10 | 2020 | 9516 | 0.250 |
Why?
|
Selectins | 1 | 2005 | 101 | 0.240 |
Why?
|
Gene Expression Regulation, Neoplastic | 11 | 2018 | 8634 | 0.230 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2830 | 0.230 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2013 | 3112 | 0.230 |
Why?
|
Cholecalciferol | 2 | 2020 | 557 | 0.220 |
Why?
|
Sirolimus | 3 | 2012 | 1542 | 0.220 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2022 | 3520 | 0.220 |
Why?
|
Neoplastic Stem Cells | 5 | 2021 | 1356 | 0.210 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2015 | 5336 | 0.210 |
Why?
|
Brain Death | 2 | 2005 | 360 | 0.210 |
Why?
|
Graft Rejection | 6 | 2012 | 4505 | 0.200 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2007 | 2952 | 0.190 |
Why?
|
Kidney Neoplasms | 6 | 2015 | 4303 | 0.180 |
Why?
|
Rheum | 1 | 2020 | 2 | 0.180 |
Why?
|
Pancreatic Neoplasms | 2 | 2016 | 5443 | 0.180 |
Why?
|
Mesenchymal Stem Cells | 2 | 2022 | 1671 | 0.180 |
Why?
|
Antibodies, Monoclonal | 3 | 2016 | 9261 | 0.170 |
Why?
|
Receptors, CXCR3 | 2 | 2012 | 241 | 0.170 |
Why?
|
HT29 Cells | 2 | 2017 | 190 | 0.170 |
Why?
|
Disease Progression | 4 | 2018 | 13646 | 0.170 |
Why?
|
Immunotherapy | 1 | 2016 | 4738 | 0.170 |
Why?
|
Adenocarcinoma | 3 | 2021 | 6406 | 0.160 |
Why?
|
Renal Insufficiency | 1 | 2005 | 809 | 0.160 |
Why?
|
HCT116 Cells | 2 | 2017 | 405 | 0.160 |
Why?
|
Immunosuppressive Agents | 3 | 2012 | 4209 | 0.160 |
Why?
|
Immunoenzyme Techniques | 3 | 2013 | 1705 | 0.160 |
Why?
|
Neoplasm Transplantation | 5 | 2015 | 2017 | 0.150 |
Why?
|
Diabetic Foot | 1 | 2022 | 383 | 0.150 |
Why?
|
Graft Survival | 4 | 2012 | 3900 | 0.150 |
Why?
|
Rats, Inbred Lew | 6 | 2009 | 1165 | 0.140 |
Why?
|
Cell Line, Tumor | 10 | 2016 | 17135 | 0.140 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2022 | 507 | 0.140 |
Why?
|
Chemokines | 2 | 2012 | 962 | 0.140 |
Why?
|
Abdominal Wall | 1 | 2018 | 167 | 0.140 |
Why?
|
Plant Extracts | 1 | 2020 | 499 | 0.140 |
Why?
|
Prognosis | 9 | 2021 | 30022 | 0.130 |
Why?
|
Neoplasms | 3 | 2016 | 22385 | 0.130 |
Why?
|
Osteopontin | 1 | 2017 | 307 | 0.130 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2020 | 669 | 0.130 |
Why?
|
Constipation | 1 | 2020 | 570 | 0.120 |
Why?
|
Neovascularization, Physiologic | 1 | 2022 | 1371 | 0.120 |
Why?
|
Flow Cytometry | 5 | 2013 | 5900 | 0.120 |
Why?
|
Mice, Inbred NOD | 6 | 2018 | 1839 | 0.120 |
Why?
|
Animals | 28 | 2022 | 169337 | 0.120 |
Why?
|
Melanoma | 5 | 2014 | 5705 | 0.120 |
Why?
|
Antibodies, Neoplasm | 2 | 2006 | 283 | 0.120 |
Why?
|
Rats, Inbred F344 | 3 | 2005 | 826 | 0.110 |
Why?
|
Tumor Cells, Cultured | 4 | 2018 | 6132 | 0.110 |
Why?
|
Toll-Like Receptor 9 | 2 | 2016 | 199 | 0.110 |
Why?
|
Caco-2 Cells | 3 | 2022 | 365 | 0.110 |
Why?
|
Toll-Like Receptors | 1 | 2016 | 582 | 0.110 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2018 | 755 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2021 | 998 | 0.110 |
Why?
|
RNA, Messenger | 7 | 2022 | 12805 | 0.100 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 13697 | 0.100 |
Why?
|
MAP Kinase Signaling System | 2 | 2016 | 1493 | 0.100 |
Why?
|
Carcinoma, Renal Cell | 3 | 2015 | 3200 | 0.100 |
Why?
|
Colectomy | 1 | 2018 | 699 | 0.100 |
Why?
|
Injections, Intraperitoneal | 1 | 2013 | 413 | 0.100 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2020 | 1943 | 0.100 |
Why?
|
Cattle | 1 | 2018 | 3826 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 11854 | 0.100 |
Why?
|
Blotting, Western | 3 | 2016 | 5037 | 0.100 |
Why?
|
Membrane Glycoproteins | 1 | 2002 | 3712 | 0.090 |
Why?
|
Humans | 42 | 2024 | 768393 | 0.090 |
Why?
|
Wound Healing | 2 | 2022 | 2813 | 0.090 |
Why?
|
Fluoxetine | 1 | 2015 | 735 | 0.090 |
Why?
|
Toll-Like Receptor 10 | 1 | 2010 | 12 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2011 | 205 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2015 | 567 | 0.090 |
Why?
|
Kidney | 3 | 2002 | 7064 | 0.090 |
Why?
|
Stromal Cells | 1 | 2016 | 1337 | 0.090 |
Why?
|
Glycoproteins | 3 | 2021 | 2204 | 0.090 |
Why?
|
Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 58 | 0.090 |
Why?
|
Collagen | 1 | 2018 | 2646 | 0.090 |
Why?
|
Mice, SCID | 5 | 2015 | 2632 | 0.090 |
Why?
|
Neoplasms, Experimental | 1 | 2015 | 1232 | 0.080 |
Why?
|
Rats | 8 | 2018 | 23835 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 4588 | 0.080 |
Why?
|
Tissue Scaffolds | 1 | 2016 | 950 | 0.080 |
Why?
|
Growth Inhibitors | 1 | 2010 | 375 | 0.080 |
Why?
|
Autoantigens | 1 | 2013 | 891 | 0.080 |
Why?
|
Aged | 11 | 2020 | 171562 | 0.080 |
Why?
|
Mice, Inbred BALB C | 7 | 2015 | 6234 | 0.080 |
Why?
|
Neoplasm Metastasis | 4 | 2021 | 4921 | 0.080 |
Why?
|
Drug Delivery Systems | 1 | 2020 | 2237 | 0.080 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 615 | 0.080 |
Why?
|
Immunohistochemistry | 4 | 2018 | 11120 | 0.080 |
Why?
|
Cell Culture Techniques | 1 | 2016 | 1667 | 0.080 |
Why?
|
Transplantation, Homologous | 6 | 2012 | 4834 | 0.080 |
Why?
|
Middle Aged | 12 | 2024 | 223491 | 0.070 |
Why?
|
Signal Transduction | 6 | 2016 | 23631 | 0.070 |
Why?
|
Cyclooxygenase 2 | 1 | 2010 | 599 | 0.070 |
Why?
|
T-Lymphocyte Subsets | 2 | 2006 | 1813 | 0.070 |
Why?
|
Neovascularization, Pathologic | 2 | 2022 | 2635 | 0.070 |
Why?
|
Antigens, CD | 3 | 2021 | 4031 | 0.070 |
Why?
|
Clone Cells | 2 | 2009 | 1671 | 0.070 |
Why?
|
Down-Regulation | 2 | 2012 | 2940 | 0.070 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2011 | 646 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 560 | 0.070 |
Why?
|
Tissue Donors | 2 | 2011 | 2389 | 0.070 |
Why?
|
Mice | 14 | 2022 | 82017 | 0.070 |
Why?
|
Nerve Compression Syndromes | 1 | 2008 | 160 | 0.070 |
Why?
|
Disease Models, Animal | 3 | 2010 | 18362 | 0.070 |
Why?
|
Proteinuria | 3 | 2005 | 613 | 0.070 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2010 | 567 | 0.070 |
Why?
|
Skin | 2 | 2020 | 4499 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2010 | 957 | 0.070 |
Why?
|
Peptides | 3 | 2021 | 4353 | 0.070 |
Why?
|
Cell Movement | 1 | 2018 | 5215 | 0.060 |
Why?
|
Fluorouracil | 1 | 2011 | 1655 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2018 | 3617 | 0.060 |
Why?
|
Fibroblasts | 1 | 2016 | 4177 | 0.060 |
Why?
|
Intestinal Mucosa | 1 | 2016 | 3048 | 0.060 |
Why?
|
Survival Rate | 3 | 2018 | 12870 | 0.060 |
Why?
|
Survival Analysis | 3 | 2013 | 10117 | 0.060 |
Why?
|
Autophagy | 1 | 2012 | 1351 | 0.060 |
Why?
|
Male | 18 | 2024 | 364902 | 0.060 |
Why?
|
Th2 Cells | 3 | 2006 | 1079 | 0.060 |
Why?
|
Cell Hypoxia | 2 | 2017 | 662 | 0.060 |
Why?
|
Liver Neoplasms | 3 | 2010 | 4365 | 0.060 |
Why?
|
Creatinine | 2 | 2011 | 1915 | 0.060 |
Why?
|
Combined Modality Therapy | 2 | 2013 | 8562 | 0.060 |
Why?
|
Chronic Disease | 6 | 2020 | 9379 | 0.060 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 1766 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2010 | 6541 | 0.050 |
Why?
|
Nerve Regeneration | 1 | 2008 | 799 | 0.050 |
Why?
|
Gene Expression | 4 | 2015 | 7598 | 0.050 |
Why?
|
Immune Tolerance | 2 | 2009 | 2324 | 0.050 |
Why?
|
Tissue Array Analysis | 2 | 2018 | 551 | 0.050 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2022 | 178 | 0.050 |
Why?
|
Immunologic Techniques | 1 | 2002 | 213 | 0.050 |
Why?
|
Female | 14 | 2021 | 397089 | 0.050 |
Why?
|
Mice, Nude | 4 | 2010 | 3632 | 0.050 |
Why?
|
Lymphatic Metastasis | 2 | 2007 | 2925 | 0.050 |
Why?
|
Monitoring, Intraoperative | 1 | 2008 | 950 | 0.050 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2022 | 183 | 0.050 |
Why?
|
Coculture Techniques | 2 | 2016 | 1342 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 3722 | 0.050 |
Why?
|
Histocompatibility Antigens | 1 | 2002 | 478 | 0.050 |
Why?
|
Dermis | 1 | 2022 | 203 | 0.050 |
Why?
|
Skin Neoplasms | 2 | 2011 | 5857 | 0.050 |
Why?
|
Prospective Studies | 3 | 2020 | 54920 | 0.050 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2010 | 2846 | 0.050 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2022 | 368 | 0.040 |
Why?
|
Solubility | 1 | 2002 | 1085 | 0.040 |
Why?
|
Rats, Wistar | 2 | 2018 | 1890 | 0.040 |
Why?
|
Interferon-gamma | 4 | 2010 | 3164 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2006 | 1105 | 0.040 |
Why?
|
Epidermal Growth Factor | 1 | 2022 | 698 | 0.040 |
Why?
|
Microarray Analysis | 2 | 2014 | 753 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2010 | 4646 | 0.040 |
Why?
|
Membrane Proteins | 2 | 2013 | 7880 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2011 | 3610 | 0.040 |
Why?
|
Arthritis | 1 | 2024 | 684 | 0.040 |
Why?
|
Cell Lineage | 1 | 2008 | 2574 | 0.040 |
Why?
|
Gene Expression Regulation, Enzymologic | 2 | 2015 | 1169 | 0.040 |
Why?
|
Doxorubicin | 1 | 2005 | 2229 | 0.040 |
Why?
|
Administration, Topical | 1 | 2020 | 703 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2011 | 11254 | 0.040 |
Why?
|
Cancer Vaccines | 1 | 2006 | 1042 | 0.040 |
Why?
|
Inflammation | 1 | 2018 | 10863 | 0.040 |
Why?
|
Models, Animal | 2 | 2018 | 2124 | 0.040 |
Why?
|
Quality Control | 1 | 2020 | 833 | 0.040 |
Why?
|
RNA, Small Interfering | 3 | 2011 | 3434 | 0.040 |
Why?
|
Protein Transport | 2 | 2015 | 1958 | 0.040 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2010 | 306 | 0.030 |
Why?
|
Immunomodulation | 1 | 2020 | 549 | 0.030 |
Why?
|
Cell Survival | 2 | 2017 | 5792 | 0.030 |
Why?
|
Intestine, Small | 1 | 2002 | 1218 | 0.030 |
Why?
|
Rectum | 1 | 2021 | 902 | 0.030 |
Why?
|
Heart Transplantation | 1 | 2010 | 3300 | 0.030 |
Why?
|
Lymphocytes | 1 | 2004 | 2611 | 0.030 |
Why?
|
Surgical Instruments | 1 | 2018 | 386 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2012 | 5708 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2017 | 478 | 0.030 |
Why?
|
bcl-X Protein | 1 | 2016 | 412 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2013 | 39407 | 0.030 |
Why?
|
Receptors, Interleukin-8A | 1 | 2014 | 47 | 0.030 |
Why?
|
Toll-Like Receptor 2 | 1 | 2016 | 348 | 0.030 |
Why?
|
Time Factors | 2 | 2007 | 40272 | 0.030 |
Why?
|
G1 Phase | 1 | 2015 | 403 | 0.030 |
Why?
|
Pancreatitis, Chronic | 1 | 2016 | 282 | 0.030 |
Why?
|
Ischemia | 1 | 2022 | 1900 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2002 | 1890 | 0.030 |
Why?
|
Toll-Like Receptor 4 | 1 | 2016 | 587 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2017 | 1703 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2013 | 2890 | 0.030 |
Why?
|
Interleukin-4 | 2 | 2010 | 1157 | 0.030 |
Why?
|
Swine | 2 | 2016 | 5994 | 0.030 |
Why?
|
Retrospective Studies | 2 | 2015 | 81801 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2016 | 2475 | 0.020 |
Why?
|
Treatment Outcome | 4 | 2024 | 65379 | 0.020 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2013 | 252 | 0.020 |
Why?
|
Heart Arrest | 1 | 2002 | 1516 | 0.020 |
Why?
|
Protoporphyrins | 1 | 2012 | 170 | 0.020 |
Why?
|
Tumor Escape | 1 | 2015 | 372 | 0.020 |
Why?
|
Benzenesulfonates | 1 | 2012 | 165 | 0.020 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2011 | 89 | 0.020 |
Why?
|
Interleukin-8 | 1 | 2014 | 705 | 0.020 |
Why?
|
Calcineurin | 1 | 2012 | 236 | 0.020 |
Why?
|
Receptors, Death Domain | 1 | 2010 | 31 | 0.020 |
Why?
|
Adenosine Triphosphate | 1 | 2016 | 2002 | 0.020 |
Why?
|
Transplantation | 1 | 2012 | 221 | 0.020 |
Why?
|
Niacinamide | 1 | 2012 | 418 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2018 | 2215 | 0.020 |
Why?
|
Adult | 4 | 2013 | 223640 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 3633 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4859 | 0.020 |
Why?
|
Administration, Oral | 1 | 2018 | 4039 | 0.020 |
Why?
|
ras Proteins | 1 | 2015 | 1058 | 0.020 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2010 | 199 | 0.020 |
Why?
|
Fas Ligand Protein | 1 | 2010 | 217 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2024 | 59686 | 0.020 |
Why?
|
In Situ Nick-End Labeling | 1 | 2010 | 612 | 0.020 |
Why?
|
Th1 Cells | 2 | 2006 | 1042 | 0.020 |
Why?
|
Phenylurea Compounds | 1 | 2012 | 530 | 0.020 |
Why?
|
Luciferases | 1 | 2010 | 712 | 0.020 |
Why?
|
Interleukin-10 | 2 | 2006 | 1184 | 0.020 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2011 | 378 | 0.020 |
Why?
|
Postoperative Period | 1 | 2013 | 1830 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2007 | 9433 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2014 | 1020 | 0.020 |
Why?
|
Bone Marrow Neoplasms | 1 | 2009 | 101 | 0.020 |
Why?
|
Interleukin-23 | 1 | 2009 | 200 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2012 | 1078 | 0.020 |
Why?
|
Neural Conduction | 1 | 2008 | 443 | 0.020 |
Why?
|
Tacrolimus | 1 | 2011 | 750 | 0.020 |
Why?
|
Recurrent Laryngeal Nerve | 1 | 2008 | 145 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2012 | 1151 | 0.020 |
Why?
|
Gene Knockout Techniques | 1 | 2010 | 808 | 0.020 |
Why?
|
Transplantation Tolerance | 1 | 2012 | 633 | 0.020 |
Why?
|
Keratin-20 | 1 | 2006 | 31 | 0.020 |
Why?
|
Transfection | 1 | 2014 | 5764 | 0.020 |
Why?
|
Swine, Miniature | 1 | 2008 | 965 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 1608 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12456 | 0.020 |
Why?
|
Tissue Engineering | 1 | 2016 | 1891 | 0.020 |
Why?
|
Cell Line | 2 | 2011 | 15597 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3587 | 0.020 |
Why?
|
Self Tolerance | 1 | 2006 | 123 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2011 | 1748 | 0.020 |
Why?
|
GATA3 Transcription Factor | 1 | 2006 | 163 | 0.020 |
Why?
|
Epitope Mapping | 1 | 2006 | 300 | 0.020 |
Why?
|
Cell Separation | 1 | 2010 | 1726 | 0.010 |
Why?
|
Gene Expression Profiling | 2 | 2011 | 9510 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 5891 | 0.010 |
Why?
|
Rats, Inbred WF | 1 | 2002 | 140 | 0.010 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 3939 | 0.010 |
Why?
|
Interleukin-17 | 1 | 2009 | 923 | 0.010 |
Why?
|
Cells, Cultured | 2 | 2011 | 19022 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2011 | 2886 | 0.010 |
Why?
|
Transplantation, Isogeneic | 1 | 2002 | 249 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2012 | 6318 | 0.010 |
Why?
|
Intraoperative Complications | 1 | 2008 | 1176 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 6085 | 0.010 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2005 | 677 | 0.010 |
Why?
|
Up-Regulation | 1 | 2010 | 4142 | 0.010 |
Why?
|
HLA-DR Antigens | 1 | 2002 | 607 | 0.010 |
Why?
|
Point Mutation | 1 | 2006 | 1594 | 0.010 |
Why?
|
Pyridines | 1 | 2012 | 2889 | 0.010 |
Why?
|
Cell Division | 1 | 2008 | 4479 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2018 | 22296 | 0.010 |
Why?
|
Kidney Tubules | 1 | 2002 | 448 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2011 | 5801 | 0.010 |
Why?
|
Models, Biological | 1 | 2016 | 9493 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2011 | 2909 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2008 | 2394 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2010 | 5496 | 0.010 |
Why?
|
Glomerulosclerosis, Focal Segmental | 1 | 2002 | 336 | 0.010 |
Why?
|
Acute Disease | 1 | 2009 | 7242 | 0.010 |
Why?
|
Immunization | 1 | 2002 | 1219 | 0.010 |
Why?
|
Living Donors | 1 | 2002 | 651 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2011 | 7599 | 0.010 |
Why?
|
Atrophy | 1 | 2002 | 1648 | 0.010 |
Why?
|
Risk Assessment | 1 | 2018 | 24318 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2006 | 5313 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2010 | 14481 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2010 | 10267 | 0.010 |
Why?
|
Stem Cells | 1 | 2005 | 3539 | 0.010 |
Why?
|
Phenotype | 1 | 2010 | 16721 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2010 | 22355 | 0.010 |
Why?
|
Risk Factors | 1 | 2018 | 74962 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 11918 | 0.000 |
Why?
|
Mutation | 1 | 2006 | 30228 | 0.000 |
Why?
|